fbpx
Try Relivion for 60 Days

IN THE NEWS

Read the latest news about Neurolief and Relivion.

2024

Neurolief Presents Groundbreaking Study Results of its Proliv™Rx Brain Neuromodulation Therapy for Treating Major Depression at the 7th Annual Neuropsychiatric Drug Summit

Neurolief Depression Study

Neurolief Announces Breakthrough Results from Pivotal Clinical Trial of Brain Neuromodulation System for Treating Major Depressive Disorder

Neurolief’s Relivion® Secures Regulatory Approval in Japan, Pioneering At-Home Migraine Treatment

2023

Neurolief Announces Strategic Equity Investment by Sawai Group Holdings

Neurolief Appoints Neurotechnology Business Leader Steve Beller as Chief Commercial Officer

Positive Results from the MOOD Trial Interim Analysis: Brain Neuromodulation Therapy for Major Depressive Disorder

New Data at AHS Demonstrate Substantial Results for Patients Using Neurolief's Digital Therapeutics Technology to Treat Migraine

Neurolief Appoints Experienced Finance Executive as Chief Financial Officer

Neurolief Launches a New U.S. Telehealth Channel Increasing Patient Access to the Relivion MG Migraine Therapy

Archive

Neurolief Appoints Neuromodulation Industry Leader Scott Drees as CEO

Neurolief Announces Publication of the RIME Pivotal Study for Relivion MG – a Digital Therapeutics Platform for Migraine

New Data Demonstrates Substantial Reduction of Migraine Days Using Neurolief’s Digital Therapeutics Technology

First Patient Enrolled in Clinical Study Evaluating Its Brain Neuromodulation System in Treating Major Depressive Disorder

Neurolief and Sawai Enter into Exclusive Development and Marketing Agreement for Relivion®

Neurolief Announces Positive Results From RIME Clinical Study of Its Brain Neuromodulation System for Treating Acute Migraine

Relivion® Wearable Brain Neuromodulation Technology Cleared by FDA for the Treatment of Migraine

Neurolief Announces Exclusive Licensing Agreement with NeuroFront for Development and Commercialization of Relivion® in Greater China and South Korea

Neurolief’s Digital Therapeutics Neuromodulation System May Challenge Medication Therapies for the Treatment of Migraine

American Headache Society: Combined Occipital & Trigeminal Neurostimulation (Abstract)

Relivion Cleared in Europe – Granted based on data from RCT clinical trial

Neurolief Awarded Breakthrough Device Designation from FDA for Wearable Technology to Address Major Depression

Digital therapeutic device safe, effective in acute migraine

This Headset Could Treat Migraines

Neurolief gets CE-Mark for digital migraine treatment device

MedTech Strategist

European Headache Federation Conference: Brain Neuromodulation Digital Therapeutics

This Headset Could Treat Migraines

BrainTech Conference: Fighting the Opioids Crisis With Brain Neuromodulation Digital Therapeutics

NYC Neuromodulation Conference : Relivion Combined Stimulation Vs. Single Nerve Stim

NYC Neuromodulation Conference: Relivion for Rapid Pain Reduction in Occipital Migraine

ISRAEL 21C: Portable wearable device will offer over-the-counter alternative to pills or surgery to be used as needed

International Headache Society Conference 2017: Published Results of the Relivion OS-TNS Clinical Trial

Globes: Neurolief Develops Non-Invasive Migraine Treatment

ZWISCHENZEILEN: Israelis entwickeln Gerät zur Migränebehandlung (in German)

JNS: Israeli Breakthrough Device Developed to Aid Migraine Relief

Medical Device News Magazine: Neurolief’s Relivion™ Featured at Headache Symposium

Neurolief Inc.
10211 W. Sample Rd. #217
Coral Springs, FL 33065
1-888-4RELIVION (888-473-5484) 
www.relivion.com

Advanced Medical DME, LLC
10211 W. Sample Rd. #217
Coral Springs, FL 33065
Phone: 754-812-1935
Fax: 954-775-0151
support@relivion-medical.com

Neurolief Ltd.
12 Giborei Israel
Netanya, Israel 4250412
+972-9-3730288
www.relivion.com

Instagram Youtube Facebook Linkedin
©2023 Neurolief and Relivion® All Rights Reserved.